Venatorx Pharmaceuticals' President and CEO, Christopher J. Burns, Ph.D., will present during the First Time Disclosure of Clinical Candidates at the American Chemical Society (ACS) National Meeting. The presentation entitled, “Discovery of VNRX-7145: A broad-spectrum orally bioavailable beta-lactamase inhibitor (BLI) for highly resistant bacterial infections (“superbugs”)” is scheduled for Wednesday, April 3, 2019 at 10:35am ET in the Valencia Ballroom A at the Orange County Convention Center in Orlando, FL.
VNRX-7145 is a novel, orally-bioavailable BLI that is currently in clinical development. VNRX-7145, in combination with a known orally bioavailable cephalosporin, rescues the activity of the partner antibiotic against ESBLs and key carbapenem-resistant Enterobacteriaceae, including those expressing KPC and OXA carbapenemases. This presentation will explore the medicinal chemistry optimization to VNRX-7145 from less active, non-bioavailable lead compounds.
This project has been funded in part with Federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN272201600029C.